Predilife S.A. (EPA:ALPRE)

France · Delayed Price · Currency is EUR

1.300

0.00 (0.00%)

Jul 17, 2026, 11:47 AM CET

-56.95% (1Y)

Market Cap	5.13M -54.7%
Revenue (ttm)	835.81K +69.5%
Net Income	-3.93M
EPS	-1.00
Shares Out	3.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,144
Open	1.440
Previous Close	1.300
Day's Range	1.300 - 1.440
52-Week Range	1.300 - 4.000
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 22, 2026

About Predilife

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2004

Employees 21

Stock Exchange Euronext Paris

Ticker Symbol ALPRE

Full Company Profile

Financial Performance

In 2025, Predilife's revenue was 835,809, an increase of 69.47% compared to the previous year's 493,202. Losses were -3.93 million, -7.74% less than in 2024.

Financial Statements